Pinned Tweet
👇👇👇👇👇👇👇👇👇👇👇👇 – at Magdalena del Mar, Peru
What do we know about prognostic kidney lesions in #ANCA #vasculitis ? A thread. 🧵1/x
1
7
Victor Pimentel-Quiroz retweeted
#ACR26 | Vasculitis mimics
PR3-ANCA positive. Crescentic GN. The diagnosis? Sometimes, endocarditis.
Five takeaways from Prof. Benjamin Terrier’s Meet the Professor session
1️⃣ PR3+ GN + fever + low C3 → think endocarditis. Consider Bartonella and Coxiella when cultures are negative. Even a pauci-immune biopsy can occur in Bartonella endocarditis.
2️⃣ Sinusitis + stroke on immunosuppression → think mucormycosis. Urgent ENT assessment and tissue biopsy can help distinguish infection from an AAV flare.
3️⃣ Aneurysms + cytopenias + splenomegaly → think chronic active EBV. It can look like PAN. Blood EBV DNA and tissue EBER help establish the diagnosis.
4️⃣ Necrotic ear purpura + neutropenia → ask about cocaine. Dual MPO/PR3 positivity adds a clue to levamisole-associated vasculopathy.
5️⃣ New lesions despite treatment → reopen the diagnosis. Unexplained cytopenias or progressive aneurysms are clues to look for infection or haematologic disease before escalating immunosuppression.
#Vasculitis #Rheumatology #MedEd
Victor Pimentel-Quiroz retweeted
@mugartegil presented an abstract on the impact of disease activity on damage accrual in the #Lupusnet network. In total, we were authors/coauthors of 15 abstracts. Also, @VictorioPQ took part in the meeting of the #VCRC and @bhrasco and @mugartegil in the #SLICC meeting #ACR26
Victor Pimentel-Quiroz retweeted
🔥 Hot off the Press at #ACR26
ICYMI: 2026 ACR Guidelines for Management of OA (Knee/Hip/Hand)👇🏽
🆕 2026 ACR Recommendations for Management of Knee, Hip & Hand #Osteoarthritis
⬥ Behavioral/Physical vs Pharmacologic Treatments
⬥ New: GLP1 RA for Knee #OA, MTX for Erosive Hand OA?!
⬥ Treatments *not* recommended #Rheumatology
📝 ACR Guidelines⇢ tinyurl.com/ACROA2026
Victor Pimentel-Quiroz retweeted
ACR meetings are always an excellent opportunity to update our knowledge, as well as to network and reconnect with several friends. At this time, I would like to thank my mentor Prof. Chela Alarcón, for all her support over the years!
Victor Pimentel-Quiroz retweeted
🆕 2026 ACR/SAA/SPARTAN Guidelines for Treatment of Axial Spondyloarthritis #ACR26
🔸 Assessment for #AxSpA: History, Labs, Imaging
🔸 Treatment Algorithm for AxSpA: NSAIDs, TNFi, IL-17i, JAKi
🔸 Difficult-to-Treat & Non-Pharmacologic
#RheumX #AxialSpondyloarthritis #ACR2026
Victor Pimentel-Quiroz retweeted
🆕 #ACR26 The Great Debate - Diagnosing Sjogren's Disease: Is Lip Biopsy Really Necessary?
🔹Role of Salivary Gland Bx for Dx
🔹Use in SSA neg patients or ruling out mimics
🔹can see focus score ≥1 in healthy populations!
#Sjogrens #SjogrensDisease #RheumX
Victor Pimentel-Quiroz retweeted
🚨👉 Nuevas guías de tratamiento de la Enfermedad relacionada a IgG4 ya publicadas en @TheLancetRheum
🇦🇺🇧🇷🇨🇦🇨🇳🇪🇬🇫🇷🇩🇪🇮🇹🇯🇵🇲🇽🇪🇸🇸🇪🇹🇷🇬🇧🇺🇸
@IgG4ward #IgG4RD
Historia y enlace al artículo en: igg4ward.org/resources/the-i…
Victor Pimentel-Quiroz retweeted
Anti-Ro+ #pregnancy #ACR2026
Victor Pimentel-Quiroz retweeted
Are you at the #ACR26? Come and visit our poster on predictors of flares after achieving drug-free remission in the #SLICC cohort by @bhrasco @GEAS_Peru
Victor Pimentel-Quiroz retweeted
Additionally, @VictorioPQ participated in the #VCRC investigator meeting, he is actively working in some research projects of the #VCRC👏👏#ACR26
Victor Pimentel-Quiroz retweeted
Options for IgG4-RD
Exciting publication in @NEJM on obexilumab vs pbo (gc) with a nice safety profile. Look forward to more info and options on the table for this complex rare disease
Victor Pimentel-Quiroz retweeted
1/ Belimumab or anifrolumab for active nonrenal SLE?
There is no head-to-head RCT, so comparative decisions rely on indirect evidence.
Our network meta-analysis led by Marco Martinez and @PaulTejada8 included 11 RCTs and 8,607 patients.
sciencedirect.com/science/ar…
Victor Pimentel-Quiroz retweeted
𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺𝘀 𝗼𝗳 𝗔𝗡𝗖𝗔-𝗠𝗲𝗱𝗶𝗮𝘁𝗲𝗱 𝗡𝗲𝘂𝘁𝗿𝗼𝗽𝗵𝗶𝗹 𝗔𝗰𝘁𝗶𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗩𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗜𝗻𝗷𝘂𝗿𝘆
Antineutrophil cytoplasmic antibodies (ANCA)—predominantly IgG autoantibodies targeting proteinase 3 (PR3) or myeloperoxidase (MPO)—play a central pathogenic role in necrotizing small-vessel inflammation like ANCA-associated vasculitides (AAV) and granulomatosis with polyangiitis (GPA). This interconnected, non-linear pathogenic process unfolds across seven key stages:
◦ 𝗦𝘁𝗲𝗽 𝟭: Inflammatory priming. Proinflammatory cytokines, infections, and environmental cues prime neutrophils in genetically susceptible individuals, heightening their responsiveness to ANCA and complement mediators.
◦ 𝗦𝘁𝗲𝗽 𝟮: Antigen translocation. Priming induces the surface translocation of PR3 and MPO, making them accessible to circulating ANCA.
◦ 𝗦𝘁𝗲𝗽 𝟯: ANCA binding and activation. The Fab portion of ANCA binds surface PR3 or MPO, while the Fc portion engages Fc$\gamma$ receptors, triggering a respiratory burst, degranulation, and the release of reactive oxygen species (ROS) and proteolytic enzymes.
◦ 𝗦𝘁𝗲𝗽 𝟰: Endothelial injury. Activated neutrophils adhere to the endothelium, releasing proteases and ROS that impair vascular barrier integrity and drive necrotizing injury.
◦ 𝗦𝘁𝗲𝗽 𝟱: NET dysregulation. Enhanced formation and impaired macrophage-mediated clearance of neutrophil extracellular traps (NETs)—composed of DNA, histones, and enzymes—expose autoantigens, cause endothelial toxicity, and promote thrombosis.
◦ 𝗦𝘁𝗲𝗽 𝟲: Complement amplification. Neutrophil products and NET-induced injury activate the alternative complement pathway, generating C5a. C5a acts as a potent chemoattractant and priming mediator that further amplifies neutrophil activation and vascular damage.
◦ 𝗦𝘁𝗲𝗽 𝟳: Self-amplifying loop. Persistent neutrophil activation, endothelial damage, NET accumulation, and complement amplification establish a self-sustaining cycle of immune recruitment and tissue ischemia.
Neutrophils function as both autoimmune targets and primary effector cells in AAV. While the interplay between ANCA, neutrophils, NETs, endothelium, and complement is well-established, the precise contribution of each mechanism to coronary microvascular and myocardial injury in GPA requires further investigation.
*From: Lucki M, Grygiel-Górniak B, Lucka E, et al. From ANCA-mediated vascular injury to coronary microvascular and myocardial involvement in granulomatosis with polyangiitis: an immunocardiology perspective. Rheumatol Int. 2026;46:247.
🔗doi.org/10.1007/s00296-026-0…
Victor Pimentel-Quiroz retweeted
🧬 Seronegative Sjögren’s (~30%) = delayed Dx + lip biopsy
👉 New autoantibodies may change the game.
🔴 Anti-M3R → blocks salivation | strong diagnostic signal
🟠 12-antigen panel (GMNN, NUP50…)
➡️ 54% sensitivity | 100% specificity (Ro– SjD)
🟡 5-Ab panel (FNBP4 + SNRPC + CCL4 + M3R + KDM6B)
➡️ 46% sensitivity | 95% specificity
🟢 Anti-NA14 → picks up ~36% Ro/La– patients
🔵 Anti-AQP5 → ↓ salivary flow + ↑ disease activity
🟣 Anti-CarP → linked to severe disease + ILD (Ro-independent)
⚡ Take-home:
✅ No single marker wins
✅ Multiplex autoantibody panels = future of seronegative SjD
✅ Earlier Dx • fewer biopsies • better stratification • targeted therapy
📄 DOI: 10.1016/j.coi.2025.102722
#Sjögrens #Autoantibodies #Rheumatology #Immunology #Seronegative #PrecisionMedicine #MedTwitter #ClinicalResearch















































